sla has stated that it expects ropren (if approved) will sell...

sla has stated that it expects ropren (if approved) will sell around 300,000 courses for several russian cities and multiples for the rest of russia by 2010.
Considering in 2006 locally produced drugs on average cost US$0.58c
lets say by 2010 the average cost of loacally produced drugs sell for US$1 and sla is selling 1million courses, that doesnt give much revenue to justify a market cap of 260million where it needs around 60million in sales to justify it.
considering management are not even talking about selling ropren elsewhere other than russia sales from the rest of the world would be many years away if it gets approved .


extract from

https://www.espicom.com/prodCat.nsf/product_ID_Lookup/00000939?OpenDocument

The Market for Pharmaceuticals in
Brazil, Russia, India & China 2007

In 2006, the Russian pharmaceutical market was estimated at US$5.1 billion, equal to around US$36 per capita and comparable in size to Poland. In per capita terms, the market is similar to Ukraine. The market is split between imported products and cheap locally-produced generics, although imports are now taking a greater share of the market growth. Imports accounted for around 70% of the pharmaceutical market in 2004. The average price of an imported drug was US$3.15 in 2005, whereas the average price of a domestically-produced drug was US$0.58.